ReviewClinical pharmacokinetics1996
Clinical pharmacokinetics of zidovudine. An update.
Review in Clinical pharmacokinetics, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.Antimicrobial agents and chemotherapy · 2010Trial
- Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.Antimicrobial agents and chemotherapy · 1999Trial
- Ozonation products of zidovudine and thymidine in oxidative water treatment.Water research X · 2021Article
- Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.Annual review of pharmacology and toxicology · 2021Review
- Article
- From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II-Sensitivity to Physiological and Physicochemical Properties.CPT: pharmacometrics & systems pharmacology · 2012Article
- From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine.CPT: pharmacometrics & systems pharmacology · 2012Article
- Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.Antimicrobial agents and chemotherapy · 2008Article
- Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy.Clinical pharmacokinetics · 2005Review
- Dysregulation of mitogen-activated protein kinase signaling pathways in simian immunodeficiency virus encephalitis.The American journal of pathology · 2004Article
- Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.Paediatric drugs · 2002Review
- Delavirdine: clinical pharmacokinetics and drug interactions.Clinical pharmacokinetics · 2001Review
- Effects of liver disease on pharmacokinetics. An update.Clinical pharmacokinetics · 1999Review
- Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.Clinical pharmacokinetics · 1999Review
- Pharmacokinetics of oral zidovudine entrapped in biodegradable nanospheres in rabbits.Antimicrobial agents and chemotherapy · 1999Article
- Antiretroviral therapy for patients with HIV disease.British journal of clinical pharmacology · 1998Review
- Zidovudine.Infectious diseases in obstetrics and gynecology · 1998Review
- Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.Clinical pharmacokinetics · 1997Review
- Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.Clinical pharmacokinetics · 1996Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The battle against the acquired immune deficiency syndrome (AIDS) is now into its second decade, and substantial advancements have been made in our understanding of the complex life cycle of, and the immunopathology associated with, human immunodeficiency virus (HIV) infection, as well as of the drugs used to modify the course of disease. Zidovudine was the first agent approved for treatment of HIV disease, and since its widespread availability in 1987 the pharmacokinetic disposition and clinical effects of zidovudine have been extensively evaluated. This article reviews the absorption, distribution, metabolism and elimination characteristics of zidovudine, focusing on more recent information. In addition, factors that may or may not affect zidovudine disposition are discussed. These include selected drug interactions and concomitant disease states such as renal and hepatic insufficiency. Issues such as bodyweight normalisation, maternal-fetal transfer, pregnancy and intracellular phosphorylation are discussed in relation to the pharmacokinetics and clinical efficacy of zidovudine. Finally, information regarding the clinical pharmacodynamics of zidovudine is presented. This includes possible relationships between zidovudine pharmacokinetics and markers of efficacy and toxicity, and the significance of linking pharmacokinetic and pharmacodynamic information.
Indexed as
Identifiers
8983858What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.